Advertisement

Gynecologic Cancers

Liquid Biopsies Predict Treatment Response and Survival in Gynecologic Cancers

A new study has demonstrated for the first time that personalized circulating tumor DNA (ctDNA) biomarkers in gynecologic cancers can detect the presence...

Colorectal Cancer

CDX2 in Stage II Colon Cancer: Ready for Prime Time?

In a recent issue of The New England Journal of Medicine, Dalerba et al published an impressive article describing a novel bioinformatics approach to identifying...

Breast Cancer

Canadian Study Suggests Increased Risk of Cardiac Dysfunction With Trastuzumab-Based Regimens for Breast Cancer

In a Canadian retrospective population-based cohort study reported in the Journal of Clinical Oncology, Thavendiranathan et al found that trastuzumab...


Advertisement

More Top Stories

Multiple Myeloma

Kenneth Anderson, MD, on Multiple Myeloma Guideline Updates

Health-Care Policy

Regulators Embrace Immunotherapy

The Cancer Drug Development Forum exists to provide, as the name implies, a meeting place to bring together academia, the pharmaceutical industry, and most important regulators for full and frank discussions to facilitate anticancer drug development. In the recent past, the Cancer Drug Development...

Advertisement

Poor Understandability of Dense Breast Notifications Sent to Women Following Screening Mammography

In a study published by Kressin et al in JAMA, Nancy R. Kressin, PhD, of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine, and colleagues examined the content, readability, and understandability of dense breast notifications sent to women following screening...

CNS Cancers

Louis Burt Nabors, MD, on Primary and Recurrent Gliomas: Notable Developments in Management

Lung Cancer

Crizotinib in ROS1-Positive Metastatic Non–Small Cell Lung Cancer

On March 11, 2016, crizotinib (Xalkori) was approved for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ROS1 rearrangement–positive tumors.1,2 A U.S. Food and Drug Administration–approved test for the detection of ROS1 rearrangements in NSCLC is not currently...

Gynecologic Cancers

Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma

In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...

New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk

Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...

Issues in Oncology

Joseph O. Jacobson, MD, on Improving Cancer Care: What Works, What Doesn’t, and Why

Lung Cancer

The POPLAR Trial: PD-L1 Blockade With Atezolizumab in Second- or Third-Line Non–Small Cell Lung Cancer

The randomized phase II ­POPLAR trial—reported by Fehrenbacher and colleagues and reviewed in this issue of The ASCO Post—is another key piece of information for the medical community regarding the value of immune checkpoint blockers in second/third-line treatment of patients with non–small cell...

Advertisement

Canadian Study Suggests Increased Risk of Cardiac Dysfunction With Trastuzumab-Based Regimens for Breast Cancer

In a Canadian retrospective population-based cohort study reported in the Journal of Clinical Oncology, Thavendiranathan et al found that trastuzumab (Herceptin)-based regimens were associated with an increased risk of treatment-related cardiac dysfunction among women with breast cancer, with an...